Article
Immunology
Takumi Kumai, Hidekiyo Yamaki, Michihisa Kono, Ryusuke Hayashi, Risa Wakisaka, Hiroki Komatsuda
Summary: The success of immune checkpoint blockade has demonstrated the potential of immune cells to attack tumors. However, the non-specific activation of immune cells limits the clinical benefit to less than 20% of patients. Peptide-based immunotherapy, by targeting tumor antigens, offers a promising approach to develop tumor-specific immune responses. Recent advancements have shown that peptides, with suitable adjuvants, can elicit robust antitumor responses in both mice and humans.
Article
Oncology
Helen Cho, Joe Binder, Risini Weeratna, Michael Dermyer, Stanley Dai, Antionio Boccia, Wei Li, Shangjin Li, Karin Jooss, James Merson, Robert E. Hollingsworth
Summary: The development of therapeutic cancer vaccines remains active. Researchers have developed a vaccine-based immunotherapy regimen called VBIR, which activates the immune system by delivering T cell antigens. By combining this with anti-CTLA-4 and anti-PD-1 antibodies, the activation of T cells is amplified. Experimental results show that this combination can effectively inhibit tumor growth and has long-lasting effects in monkeys.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Biochemistry & Molecular Biology
Farzana Hossain, Shruthi Kandalai, Xiaozhuang Zhou, Nan Zhang, Qingfei Zheng
Summary: In this review, synthetic approaches for antigen-based cancer vaccines are highlighted, along with the discussion of various bioconjugation strategies. The progress of genetically modified cancer vaccines in clinical research is also summarized. Additionally, the synthesis of adjuvants and utilization of biomaterial scaffolds for enhancing immune responses are mentioned.
Article
Engineering, Biomedical
Huijuan Song, Qi Su, Yu Nie, Chuangnian Zhang, Pingsheng Huang, Shengbin Shi, Qiang Liu, Weiwei Wang
Summary: Vaccination has shown great potential in cancer immunotherapy, but achieving strong and broad therapeutic CD8 T cell immunity against tumors is challenging due to tumor heterogeneity. In this study, a bioinspired nanofibrous trivalent peptide hydrogel vaccine was constructed to mimic the structure and function of the extracellular matrix. The vaccine effectively stimulated CD8 T cell response and inhibited tumor growth in mice. This approach offers a simple and versatile platform for the development of personalized cancer vaccines.
ACTA BIOMATERIALIA
(2023)
Article
Oncology
Hemanth K. Potluri, Tun L. Ng, Michael A. Newton, Douglas G. McNeel
Summary: Antibody responses to off-target cancer-associated proteins may not necessarily indicate antigen spread, especially in vaccine strategies that use GM-CSF as an adjuvant. Evaluating T cell responses to non-target antigens is a preferred approach for detecting immune-mediated antigen spread following immunotherapies.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Cell Biology
Deepyan Chatterjee, Fiona J. Lewis, Henry J. Sutton, Joe A. Kaczmarski, Xin Gao, Yeping Cai, Hayley A. McNamara, Colin J. Jackson, Ian A. Cockburn
Summary: The study demonstrates the role of CSPRepeat in malaria immunity and suggests that truncated CSP molecules could be a potential strategy for malaria vaccination, despite the interference caused by CSPRepeat in immune responses.
Article
Multidisciplinary Sciences
Roberta De Matteis, Magdalena B. Flak, Maria Gonzalez-Nunez, Shani Austin-Williams, Francesco Palmas, Romain A. Colas, Jesmond Dalli
Summary: Inflammation is linked to colorectal cancer, and aspirin mediates its immunomodulatory effects by increasing the concentration of aspirin-triggered specialized proresolving mediators (AT-SPM) and reducing the expression of programmed cell death protein-1. These findings reveal a central role for AT-SPM in regulating inflammation-associated colorectal cancer.
Article
Medicine, Research & Experimental
Liyun Chen, Victoria Shi, Songyan Wang, Lulu Sun, Rebecca Freeman, Jasmine Yang, Matthew J. Inkman, Subhajit Ghosh, Fiona Ruiz, Kay Jayachandran, Yi Huang, Jingqin Luo, Jin Zhang, Pippa Cosper, Clifford J. Luke, Catherine S. Spina, Perry W. Grigsby, Julie K. Schwarz, Stephanie Markovina
Summary: Patients with high levels of SERPINB3 in their serum commonly experience treatment resistance and poor prognosis in cancer. The role of SERPINB3 in tumor immunity is not well understood. Through experiments on human primary cervical tumors and mouse models, it was found that SERPINB3 promoted myeloid cell infiltration and inhibited T cell function, leading to treatment resistance. Inhibition of SERPINB3 enhanced cytotoxic T cell function and improved the response to radiotherapy. These findings suggest that targeting SERPINB3 may be a potential strategy to counteract immunosuppression and improve treatment response in tumors.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Engineering, Biomedical
Qiu-Ling Zhang, Sheng Hong, Xue Dong, Di-Wei Zheng, Jun-Long Liang, Xue-Feng Bai, Xia-Nan Wang, Zi-Yi Han, Xian-Zheng Zhang
Summary: This study presents a strategy for simplifying antigen presentation by extracellular degradation of antigen proteins into peptides, leading to improved utilization of cancer antigens and enhanced cancer immunity. The approach demonstrates potential for personalized anti-cancer therapy and has implications for expanding immunology fields and translational medicine.
Article
Multidisciplinary Sciences
Xiaoqing Shi, Jiage Ding, Yanyan Zheng, Jiawe Wang, Navid Sobhani, Praveen Neeli, Gang Wang, Junnian Zheng, Dafei Chai
Summary: PLGA/PEI-HMGB1/GPC3 vaccine induced a strong and long-lasting CTL effect, inhibiting the progression and re-attack of hepatocellular carcinoma.
Review
Pharmacology & Pharmacy
Jipeng Jiang, Jie Mei, Shaoqiong Yi, Changjiang Feng, Yongfu Ma, Yang Liu, Ying Liu, Chunying Chen
Summary: The occurrence and development of tumors depend on the tumor microenvironment (TME), in which tumor associated macrophages (TAMs) and microbes play important roles. By targeting TAMs and microbes, tumor vaccine delivery can remodel TME, enhance antigen specificity and immunogenicity, and contribute to the regulation of TME.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Article
Multidisciplinary Sciences
Giulia Maria Piperno, Francesca Simoncello, Oriana Romano, Simone Vodret, Yuichi Yanagihashi, Regine Dress, Charles-Antoine Dutertre, Mattia Bugatti, Pierre Bourdeley, Annalisa Del Prete, Tiziana Schioppa, Emilia Maria Cristina Mazza, Licio Collavin, Serena Zacchigna, Renato Ostuni, Pierre Guermonprez, William Vermi, Florent Ginhoux, Silvio Bicciato, Shigekatzu Nagata, Nicoletta Caronni, Federica Benvenuti
Summary: Loss of TIM4 expression in lung tumor-associated cDC1 leads to inefficient uptake of cell-associated antigens and reduced activation of CD8+ T cells in advanced lung tumors. This contributes to immune surveillance and anti-tumor immune responses.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Mohan Li, Yian Wang, Pan Wu, Shanshan Zhang, Zhaojian Gong, Qianjin Liao, Can Guo, Fuyan Wang, Yong Li, Zhaoyang Zeng, Qijia Yan, Wei Xiong
Summary: This paper reviewed the feasibility of circular RNA (circRNA) encoding neoantigens, summarized the construction process, explained the mechanism of circRNA vaccine in vitro, and discussed the advantages and disadvantages of circRNA vaccine and possible combination with other immunotherapies.
Article
Multidisciplinary Sciences
Adham S. Bear, Tatiana Blanchard, Joseph Cesare, Michael J. Ford, Lee P. Richman, Chong Xu, Miren L. Baroja, Sarah McCuaig, Christina Costeas, Khatuna Gabunia, John Scholler, Avery D. Posey, Mark H. O'Hara, Anze Smole, Daniel J. Powell, Benjamin A. Garcia, Robert H. Vonderheide, Gerald P. Linette, Beatriz M. Carreno
Summary: Activating RAS missense mutations are common in human cancers and can be immunologically targeted. By characterizing HLA class I-restricted mKRAS epitopes, the study successfully isolated and transferred mKRAS-specific TCR to CD8(+) T cells, demonstrating cytotoxicity against mKRAS tumor cells from various origins, with lytic activity correlating with peptide-HLA class I complex abundance. Adoptive transfer of mKRAS-TCR engineered CD8(+) T cells led to tumor eradication in a xenograft model, validating mKRAS peptides as epitopes for immune therapies.
NATURE COMMUNICATIONS
(2021)
Article
Cell Biology
Stijn P. Andeweg, Harry Vennema, Irene Veldhuijzen, Naomi Smorenburg, Dennis Schmitz, Florian Zwagemaker, Arianne B. van Gageldonk-Lafeber, Susan J. M. Hahne, Chantal Reusken, Mirjam J. Knol, Dirk Eggink
Summary: A study in the Netherlands found an increased risk of infection by the Beta, Gamma, or Delta variants compared with the Alpha variant after vaccination. However, this effect was more pronounced in the first 14 to 59 days after complete vaccination. In contrast, there was no increased risk for reinfection with Beta, Gamma, or Delta variants relative to the Alpha variant in individuals with infection-induced immunity.
SCIENCE TRANSLATIONAL MEDICINE
(2023)